Neglected Diseases and Drug Discovery | Agenda Bookshop Skip to content
Online orders placed from 19/12 onward will not arrive in time for Christmas.
Online orders placed from 19/12 onward will not arrive in time for Christmas.
A32=Arnab Chatterjee
A32=Bob Jacobs
A32=Jeremy N Burrows
A32=John Overington
A32=Jonathan Vennerstrom
A32=Mark Mitton-Fry
A32=Meg Phillips
A32=Simon Campbell
A32=Simon Croft
A32=Win Gutteridge
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Michael J Palmer
B01=Timothy N.C. Wells
Category1=Non-Fiction
Category=MMG
Category=MMRT
COP=United Kingdom
Delivery_Delivery within 10-20 working days
Language_English
NWS=Volume 14
PA=Available
Price_€100 and above
PS=Active
SN=Drug Discovery
softlaunch

Neglected Diseases and Drug Discovery

English

There are about 8 million deaths each year from neglected tropical diseases (NTDs) in the underdeveloped world, whilst drug discovery focus and practice is only recently taking on greater urgency and embracing the latest technologies. This unique book is a state of the art review of drug discovery in respect of NTDs and highlights best practice to guide the ongoing drug discovery effort and also to raise debate and awareness in areas that remain highly neglected. All the major diseases such as malaria, trypanosomatids and TB are covered, with a review of each disease and established compounds, new mechanistic classes and new horizons. Each chapter highlights the key science that has led to breakthroughs, with detailed assessment of the key medicinal chemistry involved, and critical appraisal of new emerging approaches. Later chapters highlight under publicized disease areas where the medical needs are neglected and research is very limited, to raise awareness. The editors, acknowledged experts in the field, have a wealth of experience in successful drug discovery practice and tropical diseases.

See more
Current price €138.69
Original price €145.99
Save 5%
A32=Arnab ChatterjeeA32=Bob JacobsA32=Jeremy N BurrowsA32=John OveringtonA32=Jonathan VennerstromA32=Mark Mitton-FryA32=Meg PhillipsA32=Simon CampbellA32=Simon CroftA32=Win GutteridgeAge Group_Uncategorizedautomatic-updateB01=Michael J PalmerB01=Timothy N.C. WellsCategory1=Non-FictionCategory=MMGCategory=MMRTCOP=United KingdomDelivery_Delivery within 10-20 working daysLanguage_EnglishNWS=Volume 14PA=AvailablePrice_€100 and abovePS=ActiveSN=Drug Discoverysoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 156 x 234mm
  • Publication Date: 04 Nov 2011
  • Publisher: Royal Society of Chemistry
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9781849731928

About

Michael J Palmer is a Senior Principal Scientist at Pfizer. He has worldwide medicinal chemistry and drug discovery based experience across many different therapeutic areas. He is a member of the drug discovery teams responsible for carduraTM additional cardiovascular agents that progressed to man and cardiovascular and antiviral agents in Phase I and II stages of development. Timothy NC Wells is Chief Scientific Officer at Medicines for Malaria Venture Geneva Switzerland.

We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept